Erythropoietin Drugs Industry - Regional Scope
North America Market Forecast
North America industry is expected to dominate majority revenue share of 26.6% by 2037, The market in the region is largely driven by high prevalence rates of chronic CKD and cancer, which often result in anemia. Also, the region leads the global erythropoietin drugs markets, benefiting from substantial healthcare investment, which supports a growing acceptance and availability of EPO drugs among healthcare providers and patients.
In the U.S. there is a growing prevalence of chronic kidney disease requiring EPO and increasing availability of biosimilars. According to the Centers for Disease Control and Prevention (CDC), as of 2023, about 35.5 million are estimated to have CKD. Anemia, often a complication of CKD, is prevalent in about 20-50% of patients with CKD, depending on the stage, leading to higher EPO drug demand. Moreover, new cancer cases reached more than 2 million in 2024, according to the American Cancer Society. EPO is commonly used to treat anemia in chemotherapy patients, adding to market growth.
In Canada, public health campaigns and initiatives by organizations like the Kidney Foundation of Canada have raised awareness about CKD and anemia. The Kidney Foundation partnered with Can-SOLVE CKD, a unique patient-oriented kidney research network. In 2022, the Canadian Institutes of Health Research announced a USD 3.75 million funding commitment to Can-SOLVE CKD, which will be matched by more than USD 8 million raised through the generous assistance of over 60 partners. Early detection efforts result in higher treatment rates, which supports the demand for EPO drugs. Further, government investments in healthcare and specific initiatives focused on CKD and cancer treatment are helping expand the erythropoietin drugs market.
APAC Market Analysis
The Asia Pacific erythropoietin drugs market is experiencing robust growth, largely driven by the increasing prevalence of anemia-related conditions, such as CKD, cancer, and HIV, especially in developing countries like China and India. The increased demand for low-cost therapies has prompted the development of biosimilars for EPO.
The Government of China focus on growing the biotech and pharmaceutical sectors has spurred domestic production and innovation in biologics, including EPO drugs. The country has been heavily investing in its healthcare infrastructure and expanding public and private insurance coverage, making treatments like EPO more accessible and affordable for a larger population.
India has one of the highest rates of anemia globally, particularly among women and children. Anemia related to CKD, chemotherapy, and other health conditions is driving demand for EPO drugs. The Government of India initiatives like Ayushman Bharat (Pradhan Mantri Jan Arogya Yojana), aim to provide accessible healthcare to the population, which includes treatments for conditions like anemia and kidney disease. Also, India has been increasing the number of dialysis centers and hospitals, especially in urban and semi-urban areas, which supports the demand for EPO drugs as a standard treatment in dialysis care.
